Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $20.4 million.

  • CG Oncology's Accumulated Expenses rose 80.27% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 80.27%. This contributed to the annual value of $14.7 million for FY2024, which is 40.43% up from last year.
  • As of Q3 2025, CG Oncology's Accumulated Expenses stood at $20.4 million, which was down 11.08% from $23.0 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Accumulated Expenses peaked at $23.0 million during Q2 2025, and registered a low of $5.1 million during Q1 2024.
  • For the 3-year period, CG Oncology's Accumulated Expenses averaged around $13.5 million, with its median value being $13.0 million (2024).
  • Data for CG Oncology's Accumulated Expenses shows a peak YoY soared of 222.36% (in 2025) over the last 5 years.
  • Over the past 3 years, CG Oncology's Accumulated Expenses (Quarterly) stood at $10.4 million in 2023, then soared by 40.43% to $14.7 million in 2024, then surged by 80.27% to $20.4 million in 2025.
  • Its Accumulated Expenses stands at $20.4 million for Q3 2025, versus $23.0 million for Q2 2025 and $15.7 million for Q1 2025.